Linea de recerca // Línea de investigación
Cachexia is defined as a state of malnutrition and physical exhaustion and includes weight loss (up to 80% of lean and fat mass) due to a chronic disease. Cachexia occurs in many diseases such as cancer, acquired immunodeficiency syndrome, sepsis, diabetes, states immobilization, severe burns, chronic obstructive pulmonary disease, cardiovascular disease or old age, among others. Several studies associate the presence of wasting in patients with a decreased ability to survive. This means that there is a growing interest in developing drugs capable of dealing with this syndrome, drugs that would allow patients to cope with this disease and possess a higher quality of life in the meantime.
Nowadays there is no effective pharmaceutical treatment on the market that can resolve cachexia. Today, patients suffering with cachexia receive treatments (that is, if they are treated; it is not a common hospital practice) based on different types of drugs, which are mainly derived from progesterone (in particular, megestrol acetate) and steroids such as testosterone, nandrolone or ostarine.
Our research aims are the following:
a) to develop a combined therapy to stop muscle wasting associated with cancer cachexia.
b) to develop a score to be able to stage the cachectic syndrome taking into consideration both the metabolic and functional changes that take place during cancer cachexia.
Components del grup BBMC
Josep Mª Argilés (Catedràtic) jargiles@ub.edu
Francisco J. López-Soriano (Professor Titular) flopez@ub.edu
Sílvia Busquets (Professora Lectora) silviabusquets@ub.edu
Míriam Toledo (Becària predoctoral)
Angelica Betancourt (Becària predoctoral)
Enrica Marmonti (Becària predoctoral)
Jessica Bria (Estudiant Màster)
Maria Schöller (ERASMUS)
Guillem Lambies (Estudiant de Grau)
Melania Luque (Estudiant de Grau)
No hay comentarios:
Publicar un comentario en la entrada